Company: RGNT
Filing Date: 2025-09-30
Form Type: F-1/A
Source: 0001213900-25-093302
Chunk: 270

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-09-30
Form: F-1/A
Chunk 270
---
 | $ | 278 |   |
| Changes in fair value           |     |   | (57 | ) |
| Balance as of December 31, 2023 |     | $ | 221 |   |
| Changes in fair value           |     |   | (61 | ) |
| Balance as of December 31, 2024 |     | $ | 160 |   |

The Company has performed a sensitivity
analysis of the warrant liability which is classified as level 3 financial instruments. The Company recalculated the value of the warrants
by applying a +/- 5.0% changes to the input variables in PWERM. As of December 31, 2024, a 5.0% decrease in discount rate would increase
the fair value of the warrants to $164; a 5.0% increase in discount rate would decrease the fair value of the warrants to $156.

On March 1, 2025, the
warrants expired in accordance with their terms and were not exercised.

| b. | As part of the 2021 CLAs (see note 6b), the Company issued to the 2021 CLA investors additional warrants                            
 which will be exercisable, to the most senior class of the securities then issued and outstanding, from the 2021 CLA Maturity Date, 
 during 2023. The number of shares issued upon exercise of the warrant will be calculated by dividing 150.0% of the principal of the 
 2021 Notes by the 2021 CLA Conversion Price. The exercise price of each warrant will be 125.0% of the 2021 CLA Conversion Price.    |

Upon the occurrence of an Exit Event
(IPO or a merger and acquisition), the warrants will be exercisable to the same securities issued to the 2021 Note holders upon conversion
of the 2021 Note at the Mandatory conversion (see Note 6b). The number of shares issued upon exercise of the warrant will be calculated
by dividing 150.0% of the 2021 CLA Amount by the 2021 CLA Conversion Price. The exercise price of each warrant will be 125.0% of the
2021 CLA Conversion price.

<div align='center'>F-19</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

| NOTE 7:- | WARRANT